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ABSTRAK
Tujuan: untuk menilai kadar antibodi toksin anti-tetanus (anti-TTA) pada pasien dengan diabetes mellitus 
(DM) tipe 2 dan kelompok kontrol. Metode: secara keseluruhan, 100 pasien dengan DM tipe 2 dan 100 orang 
sehat dengan usia dan jenis kelamin yang sesuai diikutsertakan dalam penelitian. Diagnosis DM tipe 2 dipastikan 
menurut kriteria klinis dan para-klinis, misalnya kadar glukosa darah puasa di atas 126 mg/dl. Sampel darah 
perifer diambil dari seluruh subjek penelitian. Sampel serum peserta penelitian diperiksa untuk mengukur kadar 
anti-TTA dengan metode ELISA. Kadar antitoksin di dalam serum ≥0,1 IU/mL ditentukan sebagai kadar antibodi 
protektif. Hasil: tingkat seroprotektif di kelompok sehat lebih tinggi secara bermakna daripada kelompok diabetes 
(99% vs. 92%; p<0,02). Titer rata-rata anti-TTA pada kelompok orang sehat (5,32±0,26 IU/ml) secara bermakna 
lebih tinggi daripada pasien diabetes (3,46±0,26 IU/ml; p<0,001). Pada pria penderita diabetes, nilai rata-rata 
titer anti-TTA ternyata lebih tinggi secara bermakna dibandingkan dengan wanita penderita diabetes (3,94±0,34 
IU/ml vs. 2,59±0,36 IU/ml; p<0,01). Pada pasien diabetes, tingkat seroprotektif dan nilai rata-rata titer anti-TTA 
pada subjek penelitian berusia >40 tahun juga lebih rendah daripada mereka yang berusia <40 tahun (89,23% 
vs. 97,14%; p<0,15 dan 4,57±0,38 IU/ml vs. 2,86±0,32 IU/ml; p<0,002). Nilai rerata titer anti-TTA lebih tinggi 
secara bermakna pada pasien yang menderita diabetes <5 tahun dibandingkan pasien yang menderita penyakit 
tersebut >5 tahun (3,91±0,35 IU/ml vs. 2,85±0,38 IU/ml; p<0,04). Kesimpulan: Hasil penelitian menunjukkan 
bahwa terdapat kadar anti-TTA yang lebih rendah pada pasien dengan DM tipe 2, pada wanita penderita diabetes, 
pada pasien berusia >40 tahun, dan pada pasien yang telah menderita diabetes >5 tahun.
Kata kunci: imunitas, tetanus, antibody, diabetes tipe 2
ABSTRACT
Aim: to evaluate the serum levels of anti-tetanus toxin antibodies (anti-TTA) in patients with type 2 
diabetes mellitus (DM) and in a control group. Methods: totally, 100 patients with type 2 DM and 100 age- 
and sex-matched healthy individuals were enrolled to study. The presence of type 2 DM confirmed according 
to the clinical and para-clinical criteria such as fasting plasma glucose above 126 mg/dl. A peripheral blood 
sample was collected from all subjects. The serum samples of participants tested for the levels of anti-TTA by 
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INTRODUCTION
Tetanus is an infectious disease caused by 
neurotoxin secreted from the gram-positive 
anaerobic bacillus Clostridium (C) tetani. 
Despite being preventable with an effective 
vaccine, tetanus remains a significant cause of 
morbidity and mortality worldwide.1
Contamination of wounds with spores of 
Clostridium tetani usually causes tetanus, due to 
release of neurotoxin. Tetanus is rare in people 
with history of complete vaccination course. 
However, inadequate tetanus toxoid vaccination 
and wound prophylaxis are associated with 
tetanus. Risk for fatal disease is also reported 
to be higher in patients with 65 years of age 
and older.2 The current Advisory Committee on 
Immunization Practices and Centers for Disease 
Control and Prevention recommendation propose 
diphtheria, tetanus, and acellular pertussis (DTaP) 
at ages 2, 4, 6, 15-18 months with a booster at 4-6 
years.1 In Iran, immunization against diphtheria, 
tetanus and pertussis has been applied since 
1950 with using a local vaccine manufactured by 
Razi Institute (Razi-DTwP).3 In most countries, 
booster immunization of diphtheria and tetanus 
is recommended to be performed every 10 years. 
Booster Td vaccine is recommended to start at 
the age of 11-12 years old.4
The prevalence of type 2 DM in Iran has 
been reported to be 24% in individuals with age 
>40 years and 5.5% in those aged 15-65 years.5,6 
Similar results have been reported in other 
studies.7 It has been reported that the ulceration 
and some infectious diseases are common in 
diabetic patients.8 This susceptibility to infections 
has been associated to impaired immune system 
in diabetic patients.9 Foot ulcers are also sizable 
in diabetic patients.8 The vulnerability of diabetic 
patients to slow-healing foot ulcers may provide 
a route for C. tetani spores and subsequent 
tetanus infection.8,10 Contamination of a these 
ulcers with spores of C. tetani may result to 
tetanus. Accordingly, it is expectable that the 
incidence of tetanus among diabetics patients is 
greater than non-diabetics subjects. The results of 
the some studies have demonstrated the diabetic 
patients were more susceptible to tetanus.11,12 
Moreover, it has been reported that the incidence 
of tetanus was higher in diabetic patients as 
compared to non-diabetics.13 The results of a 
study from United States have demonstrated 
the highest average annual incidence rate of 
tetanus among persons aged ≥60 years (0.35 
cases/million population) and also among old 
adults (aged ≥60 years) with diabetes (0.70 cases/
million population).13 These studies indicate a 
higher risk of tetanus in diabetics and therefore 
the implication of the vaccination against tetanus 
has been recommended for diabetic patients, 
especially in those over 50 years of age.11,13,14 This 
study is conducted to evaluate the serum levels 
of anti-TTA in patients with type 2 DM and in a 
healthy control group.
METHODS
From August 2012 to December 2012, a 
cross-sectional seroprevalence study was carried 
out in Rafsanjan (a city that located in South-East 
ELISA method. The serum antitoxin concentration ≥0.1 IU/mL was considered as a protective level of antibody. 
Results: the seroprotective rate in healthy group was significantly higher than diabetic group (99% vs. 92%; 
p<0.02). The mean titer of anti-TTA in healthy group (5.32±0.26 IU/ml) was also significantly higher than 
diabetic patients (3.46±0.26 IU/ml; p<0.001). In diabetic men the mean titer of anti-TTA was significantly 
higher in comparison to diabetic women (3.94±0.34 IU/ml vs 2.59±0.36 IU/ml; p<0.01). In diabetic patients the 
seroprotective rate and the mean titer of anti-TTA in subjects with age >40 years was also lower in comparison 
to those with age <40 years (89.23% vs 97.14%; p<0.15 and 4.57±0.38 IU/ml vs 2.86±0.32 IU/ml; P<0.002, 
respectively). The mean titer of anti-TTA was significantly higher in patients with diabetes duration <5 years 
in comparison to patients with disease duration >5 years (3.91±0.35 IU/ml vs 2.85±0.38 IU/ml; p<0.04). 
Conclusion: these results showed lower levels of anti-TTA in patients with type 2 DM, in diabetic women, in 
patients aged >40 years and in diabetic patients with disease duration >5 years .
Key words: immunity, tetanus, antibody, type 2 diabetes.
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of Iran in Kerman province). 100 type 2 DM 
patients (mean age: 42.09±6.51 years; range: 
24 to 54 years; 64 men and 36 women) and 100 
healthy subjects (mean age: 41.12±7.65 years; 
range: 26 to 57 years; 61 men and 39 women) 
were included in the study.
As mentioned, the universal vaccination of 
infants and children against diphtheria, tetanus 
and pertussis has been incorporated in the 
national immunization scheme in Iran since 
1950.15 Accordingly all subjects born after 
this timepoint (including subjects enrolled to 
this study) received DTwP vaccine. Primary 
vaccination has been done by using 3 doses 
of vaccine at 2, 4, and 6 months of age with 3 
booster doses at age 18–24 months, 5–6 years and 
18-24 years. There was no any other vaccination 
records regarding tetanus for participants.
The type 2 DM patients selected from subjects 
referring to the Pathobiological Laboratory of 
Rafsanjan University of Medical Sciences. The 
type 2 DM patients had disease, according to the 
fasting plasma glucose above 126 mg/dl (as a 
major criteria defined by the American Diabetes 
Association) and physician’s examination. The 
healthy control group was recruited among blood 
donors of Rafsanjan Blood Transfusion Center. 
The healthy controls were basically health, 
with normal fasting plasma glucose and no 
acute or chronic illnesses. Subjects with disease 
such as history of recurrent infections, asthma, 
allergy and atopic diseases, any suspected 
immunological disorders, cigarette smoking 
and use of any drugs were all excluded from the 
study. Other exclusion criteria were malignancy, 
surgery and major trauma within 6 months prior 
to blood collection. The participants did not 
even received any immunomodulating treatment 
during 6 month prior to sampling. All participants 
had normal CBC, normal liver and normal renal 
function tests. Moreover, the blood lipids profile 
(including cholesterol and triglyceride) of all 
subjects were within normal range.
This study was evaluated and approved by 
the Ethical Committee of Rafsanjan University 
of Medical Sciences. All of participants gave 
written informed consent to take part in the study. 
Peripheral blood (2-4 milliliter) were collected 
from the subjects of 2 groups and the serum 
separated and stored at –200C. 
Determination of Anti-tetanus Toxin Specific 
Antibodies in Serum
Serum levels of anti-TTA was measured by 
an enzyme-linked immunosorbentassay (ELISA) 
method by using commercial kits (IBL-Hamburg 
GmbH, Hamburg, Germany). Principally, the 
wells of ELISA plate are coated with tetanus 
toxin as antigen. Specific antibodies of the 
sample binding to the antigen coated wells are 
detected by a secondary enzyme conjugated 
antibody specific for human IgG. After the 
addition of substrate the intensity of the color 
is proportional to the amount of IgG-specific 
antibodies. Results of samples can be determined 
directly using the standard curve.
In the test procedure, after pipetting 100 μL 
of each standard and diluted serum (1/100) into 
the respective wells, plates were incubated for 60 
min at 25 C. At the end of the incubation period, 
plate strips were washed four times with 300 μL 
washing buffer per well. Then, 100 μL conjugate 
was added into each well. After the incubation 
period (for 30 min at 250C), plate strips were 
washed as previously described. Thereafter, 100 
μL of Tetramethylbenzidine (TMB) substrate 
solution was added into each well and incubated 
for 20 min at 250C in dark. The substrate reaction 
was stopped by addition 50 μL of sulfuric acid 
into each well. Optical density of each well 
measured with a photometer at 450 nm within 
60 min after pipetting of the stop solution. 
Anti-TTA was measured by using standard 
samples with known concentrations of anti-
TTA expressed as IU/mL, provided by the 
manufacturer. According to manufacturer 
guideline, an antitoxin concentration ≥0.1 IU/mL 
was considered as protective level of antibody. 
Tetanus antitoxin levels less than 0.1 IU/ml 
were considered to denote susceptibility. The 
sensitivity of ELISA kit was 0.004 IU/ml.
Statistical Analysis
Differences in variables were analyzed 
using t-test and chi-square test as appropriate 
and P-values of less than 0.05 were considered 
significant. All data were analyzed by SPSS 
software (version 15, Chicago, IL).
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RESULTS
The seroprotective rate of anti-TTA in 
healthy control group (99%) was significantly 
higher than that observed in diabetic group 
(92%, P<0.02). The mean titer of anti-TTA in 
healthy control group (5.32±0.26 IU/ml) was also 
significantly higher than that in diabetic patients 
(3.46±0.26 IU/ml; P<0.001).
In diabetic men the mean titer of anti-TTA 
was significantly higher in comparison to 
diabetic women (3.94±0.34 IU/ml vs 2.59±0.36 
IU/ml; P<0.01). In healthy men the mean titer 
of anti-TTA was higher than that observed 
in healthy women but the difference was not 
statistically significant (Table 1). In both diabetes 
and control groups no significant difference was 
observed between men and women with respect 
to the seroprotection rate (Table 1).
In diabetic patients the mean titer of anti-TTA 
in subjects with age >40 years was significantly 
lower in comparison to those with age <40 years 
(4.57±0.38 IU/ml vs 2.86±0.32 IU/ml; p<0.002). 
In healthy control group the mean titer of anti-
TAA in subjects with age >40 years was also 
lower than that observed in those aged <40 years 
but the difference was not statistically significant 
(5.85±0.40 IU/ml vs 4.99±0.35 IU/ml; p=0.12). 
(Table 2). In diabetes group the seroprotection 
rate was lower in patients with age >40 years as 
compared with patients with age <40 years but 
the difference was not statistically significant 
(89.23% vs 97.14%; p=0.15). Moreover, in 
healthy control groups no significant difference 
was observed between subjects with age >40 
years and subjects with age <40 years with 
respect to seroprotection rate (Table 2).
According to the duration of the diabetes the 
patients divided into two subgroups, 57 patients 
were diabetic for <5 years and 43 patients were 
diabetic for >5 years. The mean titer of anti-TTA 
was significantly higher in patients with diabetes 
duration <5 years in comparison to patients 
with disease duration >5 years (3.91±0.35 IU/
ml vs 2.85±0.38 IU/ml; p<0.04). No significant 
difference was observed between patients 
with disease duration <5 years and patients 
with diabetes duration <5 years with respect 
to seroprotection rate, although this parameter 
Table 1. Serum concentrations of anti-tetanus toxin antibody in healthy and diabetic groups according to gender
Group Gender Number Protection rate  N (%)
anti-tetanus toxin antibody  
(IU/mL)
Healthy group
Men 61 60 (98.36%) 5.51±0.33†
Women 39 39 (100%) 5.02±0.45
Total 100 99 (99%) 5.32±0.26
Diabetic patients
Men 64 59 (92.18) 3.94±0.34
Women 36 33 (91.66) 2.59±0.36
Total 100 92 (92%) 3.46±0.26
† The serum levels of anti-tetanus toxin antibody expressed as mean±SEM
Table 2. Serum concentrations of anti-tetanus toxin antibody in healthy and diabetic groups according to age group
Group Age (year) Number Protection rate  N (%)
anti-tetanus toxin antibody  
(IU/mL)
Healthy group
<40 38 37 (97.36%) 5.85±0.40†
>40 62 62 (100%) 4.99±0.35
Total 100 99 (99%) 5.32±0.26
Diabetic patients
<40 35 34 (97.14%) 4.57±0.38
>40 65 58 (89.23%) 2.86±0.32
Total 100 92 (92%) 3.46±0.26
† The serum levels of anti-tetanus toxin antibody expressed as mean±SEM
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was found to be higher in patients with disease 
duration <5 years (94.7% vs 88.4).
The distribution of subjects according to their 
serum levels of anti-TTA has been demonstrated 
in Table 3. The rate of subjects with high serum 
levels of anti-TTA (>4 IU/mL) in healthy control 
group was significantly higher in comparison to 
diabetic group (70% vs 35%; p<0.001). On the 
other hand the rate of subjects with low serum 
levels of anti-TTA (<1 IU/mL) in diabetic group 
was significantly higher in comparison to healthy 
control group (19% vs 9%; p<0.05).
DISCUSSION
The results of the present study showed 
that both seroprotective rate and the mean titer 
of anti-TTA were lower in diabetic patients as 
compared with healthy control subjects. These 
findings represent that diabetic patients have a 
greater susceptibility to tetanus infection. There 
is a few studies regarding the tetanus immunity 
among type 2 DM patients. Two studies from 
Turkey have observed that the mean titer of anti-
TTA was significantly lower in patients with DM 
as compared with healthy subjects.14,16
The lower levels of anti-TTA in diabetic 
subjects can be attributed to some immune 
dysfunction in these patients. The lower 
antibody responses to other vaccines such as 
hepatitis B vaccine and influenza A vaccine 
have been also reported in patients with type 
2 DM.17,18 Moreover, it has been reported that 
diabetic patients are susceptible to infection 
and sepsis.19 Furthermore, some immunologic 
disorders have been shown in patients with 
type 2 DM. Dendritic cells (DC) play a key 
role in initiating innate and adapted immune 
responses. It has been demonstrated that 
absolute frequency of DC significantly were 
diminished in patients with type 2 DM.20 Some 
defects in humoral immunity and complement 
system also demonstrated in diabetic patients.19 
Moreover, it has been demonstrated that the 
phagocytic activity of monocytes is attenuated in 
experimentally-induced type 2 diabetes in rat.21 
Furthermore, enhanced functions of regulatory 
T-cells demonstrated in experimentally-induced 
diabetes in mice.22 Impaired functions of 
polymorphonuclear leukocyte have been also 
reported in patients with type-2 DM.23
It should be noted that the vaccination is 
one of the most significant tools for induction 
the prophylaxis against infection diseases. 
This prophylaxis mediated via inducing of 
immunologic memory.24 In addition to several 
immune dysfunctions in diabetic patients that 
mentioned above, the low levels of anti-TTA in 
diabetic patients may be also attributed in part 
to impairment of immunological memory in this 
patients.
The results of the present study also showed 
that mean titer of anti-TTA was higher in men as 
compared to women. Similar findings have been 
reported in other studies.25,26 This may be due to 
higher accident rates among men that increase 
the higher exposure to Clostridium tetani which 
results in higher protective immunity. The results 
of a study from United State have demonstrated 
the differences in the tetanus incidence rates 
between men and women that varied by age 
group. For subjects aged <20 years, the incidence 
of tetanus among men reported as 2.7 times more 
than the incidence among women and for persons 
aged 20–59 years, the incidence of tetanus 
among men reported as 2.9 times more than the 
incidence among women.13 The results of a ten-
year retrospective study from Nigeria showed 
that the male: female ratio in tetanus patients 
was 3:1.27 It has been also reported that the men 
who had a history of dirty wounds or frequent 
soil exposure have more levels of anti-TAA.26 
Moreover, a proportion of men may served in 
the army as young adults where they vaccinated 
against tetanus.25,28 Further investigation is 
needed to clarify the reasons for greater tetanus 
immunity among men than woman. However, 
Table 3. Distribution of subjects according to anti-tetanus toxin antibody in healthy and diabetic group
Groups <0.1 IU/mL 0.1-1 IU/mL 1-2 IU/mL 2-3 IU/mL 3-4 IU/mL 4-5 IU/mL >5 IU/mL
Healthy group 1% 8% 7% 8% 6% 11% 59%
Diabetic Patients 8% 11% 20% 19% 7% 5% 30%
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there was no significant difference between men 
and women of healthy control group with respect 
to the seroprotection rate, probably due to the 
tetanus booster vaccination in women performed 
during pregnancy.
The results of the present study also showed 
that the mean titer of anti-TTA in subjects with 
age >40 years was lower in comparison to those 
with age <40 years. These finding represent that 
the anti-TAA levels declined with age so that 
there is the greater the necessity for the older 
persons to receive a tetanus booster because of 
waning immunity in the older age group.
In diabetes group, the seroprotection rate 
was observed in 89.23% of patients with age 
>40 years and 97.14% of patients with age 
<40 years. Moreover, in healthy control groups 
the seroprotection rate was observed in 100% 
of subjects with age >40 years and 97.36% of 
subjects with age <40 years. It has been reported 
that the inadequate tetanus toxoid vaccination 
and wound prophylaxis are associated with 
tetanus. Risk for fatal disease is also reported to 
be higher in patients 60 years of age and older.2,29 
It should be noted that seroprotective rate against 
tetanus varies between countries. For example, 
seroprotective rate was noted in 33.9% of of 
people aged >50 years from Turkey30, in 53% of 
people aged 20-50 years from India31, in 84.7% 
of people aged 20-64 years from Brazil32, in 
70% of people aged >80 years from Germany33, 
in 53% of people aged >60 years from England 
and Wales34, and in <75% of people aged >50 
years from Australia.35 This discrepancy may be 
attributed largely to differences in the age, job 
and race of participants, the primary vaccination 
schedule, and time intervals between vaccine 
administration and collection of blood samples.
The results of the present study also showed 
that the mean titer of anti-TTA were significantly 
higher in patients with diabetic duration <5 years 
as compared to patients with disease duration 
>5 years. These results represent a negative 
association between the duration of diabetes 
and the mean titer of anti-TTA. The results of 
a investigation from Korea demonstrated that 
that the type 2 DM patients with longer duration 
of diabetes had lower seroconversion rate after 
vaccination with a type of influenza A vaccine.17 
According to serum levels of anti-TTA we 
have arbitrary classified the subjects to several 
subgroups. In healthy control group 59% of 
subjects have the anti-TTA >5 IU/mL whereas 
30% of diabetic subjects have the anti-TTA >5 
IU/mL. On other hand the proportion of subjects 
with low anti-TTA was higher in diabetes group 
in comparison to healthy control group. This 
classification can be use for designing of the re-
vaccination program. According to manufacturer 
guideline, for individuals with antitoxin level 
<0.1 IU/ml (no protection), vaccine should be 
administered. Individuals with antitoxin level 
0.1-1.0 IU/ml should be control after 1-2 years. 
Individuals with antitoxin level 1.1-5.0 IU/ml 
should be control after 2-4 years. Individuals 
with antitoxin level >5.0 IU/ml should be 
control after 8 years. Similar guideline has 
been presented for revaccination by Centers for 
Disease Control and Prevention.36
CONCLUSION
The results of the present study showed 
lower levels of anti-TTA in patients with type 
2 DM, in diabetic women and in patients aged 
>40 years. Moreover, a reverse association was 
also observed between the duration of diabetes 
and the mean titer of anti-TTA.
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